methylnaltrexone
information and resources from the National Cancer Institute
NCI Thesaurus | methylnaltrexone
A methyl derivative of noroxymorphone with selective, opioid-receptor antagonistic activity. Methylnaltrexone displaces opioids from peripheral opioid receptors in the gastrointestinal tract, the bladder, and the skin, resulting in decreases in opioid-related constipation, urinary retention, and pruritis, respectively. Methylnaltrexone does not cross the blood-brain barrier and does not affect the centrally-mediated analgesic effect of opioids. NCI Thesaurus | methylnaltrexone
A methyl derivative of noroxymorphone with selective, opioid-receptor antagonistic activity. Methylnaltrexone displaces opioids from peripheral opioid receptors in the gastrointestinal tract, the bladder, and the skin, resulting in decreases in opioid-related constipation, urinary retention, and pruritis, respectively. Methylnaltrexone does not cross the blood-brain barrier and does not affect the centrally-mediated analgesic effect of opioids.
|
|
|
|
news articles
Progenics Pharmaceuticals Reports Fourth Quarter and Year End ... Mar 15, 2006
Genetic Engineering News, ...reasons for the increases in expenses were the Company's acquisition in 2005 of certain rights for our lead investigational drug, methylnaltrexone (MNTX), from ...
Progenics posts wider 4Q loss Mar 15, 2006
BusinessWeek ...more than doubled to $35.8 million from $13.8 million a year ago due largely in part to Progenics' purchase of licensing rights for methylnaltrexone, or MNTX ...
Progenics Posts Wider-Than-Expected Q4 Loss On Higher Expenses And ... Mar 15, 2006
Trading Markets, The company attributed the higher expenses to the acquisition of certain rights for the company's lead investigational drug, methylnaltrexone from several of ...
Progenics Pharmaceuticals "buy" Dec 2, 2005
New Ratings Progenics Pharmaceuticals’ lead opioid antagonist, Methylnaltrexone, for the treatment of opioid-induced bowel dysfunction, is expected to be the first drug ...
Biotech Bets for the Fearless Dec 12, 2005
BusinessWeek Progenics' methylnaltrexone (MNTX) is in a late-stage clinical trial for treating patients with advanced medical illness (AMI), an umbrella term encompassing ...
Progenics Pharmaceuticals Initiates Clinical Trial of Viral-Entry ... Dec 1, 2005
Business Wire (press release), In symptom management and supportive care, the Company is developing methylnaltrexone (MNTX) to treat the constipation associated with opioid-based pain ...
|
|
